Reconstructing Immunity After Allogeneic Transplantation
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Immunologic Research
- Vol. 29 (1-3) , 269-282
- https://doi.org/10.1385/ir:29:1-3:269
Abstract
A major goal of our research is to reduce the graft-vs-host disease (GVHD) activity of allogeneic donor T cells in bone marrow transplantation (BMT), while preserving graft-vs-tumor (GVT) effects. Using ex vivo immunosuppressive strategies and cell-separation techniques to modulate the graft prior to transplantation, we examined the roles of different donor immune cells on GVHD and GVT effects in allogeneic mouse models. Our results demonstrate that donor-memory CD4 T cells facilitate posttransplant immunological reconstitution without causing GVHD, whereas transplantation of equal numbers of donor naïve CD4 T cells leads to fatal GVHD. The initial events of donor T cells interacting with antigen-presenting cells (APCs) in the transplant recipient appear to be critical to the development of GVT, GVHD, or anergy to alloantigens. In the setting of clinical BMT, increased numbers of donor type 2 dendritic cells (DCs) were associated with an increased rate of posttransplant relapse, and decreased rates of chronic GVHD. In a mouse transplant model, manipulation of the DC content of bone marrow grafts was achieved by depletion of CD 11b+ cells. Mice transplanted with CD11b− depleted marrow showed enhanced posttransplant expansion of memory T cells with markedly improved GVT activity and limited GVHD compared to recipients of unmanipulated marrow. A model that differentiates GVT from GVHD based on interaction of T-cell subsets with DC subsets is proposed.Keywords
This publication has 40 references indexed in Scilit:
- Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effectsTransplantation and Cellular Therapy, 2003
- Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host diseaseBlood, 2002
- Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte InfusionsThe Journal of Immunology, 2000
- Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.2000
- Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferonNature Medicine, 1999
- Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.Journal of Clinical Oncology, 1997
- Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathwaysNature, 1996
- Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]Blood, 1995
- Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host diseaseBlood, 1995
- The biology of graft-versus-host reactions.1966